Richard Lowenthal

It's about the market in general.

And the fact that there's such a huge percentage of this market that is not using epinephrine, not well-educated.

So in that context, DTC is actually important to help inform patients.

And the public service announcements we're sponsoring are really to help inform patients of the need for epinephrine.

And when they go to do the research, whether they choose epinephrine

to get Nephi or they choose to get an auto-injector, it's their choice.

But by stimulating that discussion, stimulating that research and that thinking of the patient that maybe I should get something to protect myself, that is actually a net positive for the community and the patients themselves.

So I think Nephi is a good example of a product where I think DTC is appropriate.

I won't get into it, but I can say there are some products where DTC may not be appropriate, where a patient can't make their own decision, and they have a certain type of cancer, refractory cancer with certain biomarkers, and they're not going to be capable of making that decision.

They need an expert physician in that field to make that decision for them.

So in that case, I can understand an argument why DTC may not make sense.

But in our case, I think it makes great sense.

With that said, we did get a couple what I consider to be minor comments from the Food and Drug Administration about our DTC campaign.

I don't think we agree with their comments.

I don't think advocacy agrees with their comments.

But we did make some minor adjustments to our DTC advertising to accommodate the FDA's comments.

And some of them, for example, we showed people enjoying themselves out eating.

And, of course, patients with allergy go and eat out.

They want to enjoy their life.

They don't obviously try to eat antigens.